PaiGe Biotechnology: H-share full circulation record has been approved.

PagBiotech announced that the company has received a filing notice from the China Securities Regulatory Commission regarding the implementation of full circulation of H shares. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares totaling 102 million unlisted shares. The company stated that it will apply to the Stock Exchange for approval for the listing and trading of these H shares on the main board of the Stock Exchange. Currently, the details of the implementation plan for full circulation of H shares have not been finalized.